Discussion Papers
Overview
After delivering its comprehensive report and action plan to Congress, the Commission continued to assess the biotechnology landscape and provided updated analysis in three areas to foster continued discussion in Congress and among U.S. biotechnology stakeholders in industry and academia. These new analyses represent observations from the Commission, drawn from extensive consultations from a range of expert stakeholders, that may support future policy recommendations.
Discussion papers
Future of Science
A Playbook for Accelerating American Innovation
This is an ideal moment to reimagine the federal science enterprise. The convergence of major advances in artificial intelligence and automation have created an environment where the status quo is no longer sufficient. This paper builds on the Commission’s April 2025 report by identifying ways the federal government can leverage its unique role to be a better partner throughout the innovation ecosystem. If the government changes the way it think about scientific innovation, U.S. biotechnology could generate more impact and deliver greater breakthroughs for all Americans.
The Future of U.S.-China Biotechnology Competition
This paper is an urgent update to the Commission’s April 2025 assessment of U.S.-China biotechnology competition: China’s biotechnology industry is beginning to outpace American innovation and lawmakers’ window to act is closing fast. The Commission’s assessment in its April report—that U.S. policymakers have a three-year window to retain, or in some cases regain, biotechnology leadership—must be updated. Chinese companies are beginning to outpace the U.S. in biopharmaceutical innovation, and the Chinese Communist Party’s strategy will further undercut U.S. leadership in biotechnology.
Contact us
Please fill out the contact form or email us directly at ideas@biotech.senate.gov
For press inquiries please email us at press@biotech.senate.gov
